- Home
- ITIC vs RGNX Comparison
ITIC vs RGNX Comparison
Compare ITIC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- RGNX
- Stock Information
- Founded
- ITIC 1972
- RGNX 2008
- Country
- ITIC United States
- RGNX United States
- Employees
- ITIC N/A
- RGNX N/A
- Industry
- ITIC Specialty Insurers
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ITIC Finance
- RGNX Health Care
- Exchange
- ITIC Nasdaq
- RGNX Nasdaq
- Market Cap
- ITIC 440.1M
- RGNX 387.0M
- IPO Year
- ITIC N/A
- RGNX 2015
- Fundamental
- Price
- ITIC $206.95
- RGNX $8.56
- Analyst Decision
- ITIC
- RGNX Strong Buy
- Analyst Count
- ITIC 0
- RGNX 8
- Target Price
- ITIC N/A
- RGNX $31.75
- AVG Volume (30 Days)
- ITIC 78.0K
- RGNX 1.1M
- Earning Date
- ITIC 08-05-2025
- RGNX 07-31-2025
- Dividend Yield
- ITIC 7.73%
- RGNX N/A
- EPS Growth
- ITIC 18.56
- RGNX N/A
- EPS
- ITIC 15.69
- RGNX N/A
- Revenue
- ITIC $261,197,999.00
- RGNX $156,718,000.00
- Revenue This Year
- ITIC N/A
- RGNX $327.08
- Revenue Next Year
- ITIC N/A
- RGNX N/A
- P/E Ratio
- ITIC $13.38
- RGNX N/A
- Revenue Growth
- ITIC 15.27
- RGNX 80.70
- 52 Week Low
- ITIC $173.29
- RGNX $5.04
- 52 Week High
- ITIC $290.40
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- ITIC 43.39
- RGNX 46.14
- Support Level
- ITIC $204.58
- RGNX $7.82
- Resistance Level
- ITIC $211.04
- RGNX $8.76
- Average True Range (ATR)
- ITIC 5.09
- RGNX 0.69
- MACD
- ITIC 1.63
- RGNX -0.16
- Stochastic Oscillator
- ITIC 74.52
- RGNX 24.53
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.